What does this research mean for the field?

Approximately 8.1% of hormone receptor positive, HER2-negative metastatic breast cancer patients are relapses of previously HER2-positive early-stage breast cancer, highlighting the importance of rebiopsy at recurrence. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Evaluate the natural history and care quality of patients with HR+/HER2- metastatic breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PS1-12-19: Disease natural history and care quality assessment of hormone receptor positive / human epidermal growth factor receptor 2 negative metastatic breast cancer (HR+/HER2- mBC) - an international multicentric study

View Full Paper

Ask AI

Bookmark

Evaluate the natural history and care quality of patients with HR+/HER2- metastatic breast cancer.
Identified cohorts of HR+ HER2- mBC diagnosed from 2018 to 2023 at five European centres.
Clinical data were structured according to the OMOP common data model and extracted using automated systems.
Data analysis was conducted using Vantage6 federation platform, focusing on disease history and HER2 status.
1175 HR+/HER2- mBC patients were identified, with phenotypic data for 529 patients analyzed.
33.3% of patients had de novo metastatic disease, while 66.7% experienced a relapse from early-stage cancer.
Among patients rebiopsied at relapse, 8.1% had turned HER2-positive, and 16.1% had BRCA1/2 mutations.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

International multicentric study assesses care quality and genomic factors in metastatic breast cancer, highlighting the need for rebiopsy.

Cite This Study

Theophanous et al. (2026) studied this question.

synapsesocial.com/papers/6996a879ecb39a600b3ef2fc https://doi.org/10.1158/1557-3265.sabcs25-ps1-12-19

View Full Paper

Ask AI

Bookmark

Implication

International multicentric study assesses care quality and genomic factors in metastatic breast cancer, highlighting the need for rebiopsy.

Abstract PS1-12-19: Disease natural history and care quality assessment of hormone receptor positive / human epidermal growth factor receptor 2 negative metastatic breast cancer (HR+/HER2- mBC) - an international multicentric study

Key Points

Discussion

Implication

Cite This Study

Abstract PS1-12-19: Disease natural history and care quality assessment of hormone receptor positive / human epidermal growth factor receptor 2 negative metastatic breast cancer (HR+/HER2- mBC) - an international multicentric study

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider